Stoke Therapeutics Inc (STOK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.74B
Last updated: Nov 17, 2026 at 4:15 PM ET
Stoke Therapeutics Inc (STOK) Statistics
Stoke Therapeutics (STOK) has a market cap of $1.74B and an enterprise value of $1.63B. It kept -862.07% of revenue as net income over the last 12 months. Revenue fell 86.28% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 6.16% below the market cap, as cash exceeds debt.
| Market Cap | $1.74B |
|---|---|
| Enterprise Value | $1.63B |
| Latest price (Nov 17, 2026) | $26.41 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 64.0x and 5.1x. Its year-end P/S ranged from 10.0x to 28.9x from 2022 to 2025.
| P/S Ratio | 64.0x |
|---|---|
| Forward P/S | 50.2x |
| P/B Ratio | 5.1x |
Price Statistics
The stock is down 0.38% over 52 weeks and trades 0.34% above its 50-day average.
| Beta (1Y) | 1.00 |
|---|---|
| 52-Week Change | -0.38% |
| 1-Month Change | +6.41% |
| 3-Month Change | -20.04% |
| 6-Month Change | -11.85% |
| 5-Year Change | +15.16% |
| Total Return (1Y) | -0.38% |
| Total Return (3Y CAGR) | +84.26% |
| Total Return (5Y CAGR) | -1.21% |
| Return vs SPY (1Y) | -20.24% |
| Max Drawdown (1Y) | -41.33% |
| Max Drawdown (3Y) | -66.32% |
| Sharpe Ratio (1Y) | -0.17 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $26.32 |
| 200-Day Average | $30.75 |
| 52-Week Range | $22.05 to $40.22 |
| RSI (14 Days) | 49.7 |
| Average Volume (20 Days) | 1.26M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.24x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.24x |
|---|---|
| Quick Ratio | 7.24x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -68.98% over the last 12 months, against a 5-year average of -40.10%.
| Return on Equity (ROE) | -68.98% |
|---|---|
| Return on Assets (ROA) | -59.80% |
| ROE (5Y Average) | -40.10% |
| ROA (5Y Average) | -31.13% |
| ROIC (5Y Average) | -4.63% |
| Asset Turnover | 0.07x |
| Receivables Turnover | 3.59x |
Scores
STOK has an Altman Z-Score of 16.55, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 16.55 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $28.21M over the last 12 months.
| Revenue | $28.21M |
|---|---|
| Revenue Growth (YoY) | -86.28% |
| Gross Profit | $28.21M |
| Operating Income | -$257.60M |
| Pretax Income | -$243.20M |
| Net Income | -$243.20M |
| Reported EPS (TTM) | -$3.77 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 86.70% of the $406.69M in total assets.
| Cash and Equivalents | $107.27M |
|---|---|
| Total Debt | $0 |
| Net Cash | $107.27M |
| Net Cash Per Share | $1.57 |
| Working Capital | $305.44M |
| Shareholder Equity | $352.59M |
| Book Value Per Share | $5.16 |
| Total Assets | $406.69M |
| Total Liabilities | $54.10M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $5.41M of capital spending, operating cash flow left -$215.72M of free cash flow.
| Operating Cash Flow | -$210.31M |
|---|---|
| Capital Expenditures | $5.41M |
| Free Cash Flow | -$215.72M |
| FCF Per Share | -$3.33 |
| Depreciation and Amortization | $3.39M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -913.12%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -913.12% |
| Pretax Margin | -862.07% |
| Net Margin | -862.07% |
| FCF Margin | -764.66% |
Growth
Revenue grew 145.89% a year over 3 years.
| Revenue Growth (3Y CAGR) | +145.89% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | +30.41% |
| Tangible Book Per Share Growth (2Y CAGR) | +30.41% |
Dividends and Yields
STOK does not pay a dividend. Its free cash flow yield is -11.95%.
| FCF Yield | -11.95% |
|---|---|
| Buyback Yield | -8.18% |
| Shareholder Yield | -8.18% |
Peer Position
Against 6 similar companies, STOK has the 3rd highest P/S.
P/S RatioPeer median 11.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -59.47%
| P/S Ratio | 64.0x vs 11.1x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -86.28% vs -59.47% median |
Analyst Forecast
Consensus estimates put revenue growth at -47.57% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -47.57% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About STOK
What is STOK's market cap?
Stoke Therapeutics has a market cap of $1.74B. Its enterprise value, which adds debt and subtracts cash, is $1.63B.
How many shares of STOK are outstanding?
Stoke Therapeutics has 68.36M shares outstanding. The count is up 16.64% from a year earlier.
Does STOK pay a dividend?
No. Stoke Therapeutics does not pay a dividend.
How much debt does STOK have?
Stoke Therapeutics has $0 of total debt and $107.27M of cash and equivalents, a net cash position of $107.27M.
STOK pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors